Journal of Yeungnam Medical Science

Original Article

The effect of thalidomide on visceral fat pad mass and triglyceride concentration of the skeletal muscles in rats: Ki-Hoon Kim, Chang-Bon Choi, Jong-Yeon Kim; Yeungnam Univ J Med. 2018;35(2):213-218. Published online December 31, 2018; DOI: https://doi.org/10.12701/yujm.2018.35.2.213

5,329 View
52 Download
1 Crossref

Background
Body fats, especially both of abdominal fat pad mass and skeletal muscle fat content, are inversely related to insulin action. Therefore, methods for decreasing visceral fat mass and muscle triglyceride content may be helpful for the prevention of insulin resistance.
Methods
Thalidomide, used for its anti-angiogenic and anti-inflammatory properties, was administered to rats for 4 weeks. A 10% solution of thalidomide in dimethyl sulfoxide was injected daily into the peritoneal cavity as much as 100 mg/kg of body weight.
Results
The total visceral fat pad mass in the thalidomide-treated group was 11% lower than in the control group. The size of adipocytes of the epididymal fat pad mass in the thalidomide-treated group was smaller than in the control group. The intraperitoneal thalidomide treatment increased triglyceride concentrations by 16% in the red muscle, but not in the white muscle.
Conclusion
The results suggested that intraperitoneal thalidomide treatment inhibited abdominal fat accumulation, and that the free fatty acids in the blood were preferentially accumulated in the red muscle rather than in the white muscle.

Citations

Citations to this article as recorded by

Thalidomide suppresses migration and invasion of colorectal cancer cells by inhibiting HOXB7‐mediated activation of the Wnt/β‐catenin signaling pathway
Liyang Liu, Wusong Xue
Chemical Biology & Drug Design.2024;[Epub] CrossRef

First
Prev
Page of 1
Next
Last

Search